Article - Limited access to UNIGE
Other version: http://pdn.sciencedirect.com/science?_ob=MiamiImageURL&_cid=273312&_user=9565874&_pii=S093947530800238X&_check=y&_ori...
Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients
|Published in||Nutrition, Metabolism & Cardiovascular Diseases. 2009, vol. 19, no. 9, p. 613-619|
|Abstract||BACKGROUND AND AIMS: Reduced high density lipoproteins (HDL) and increased oxidative stress are features of type 2 diabetes. Myeloperoxidase is an oxidative enzyme partly associated with HDL and causing HDL dysfunction. It is an independent risk factor for cardiovascular disease. Paraoxonase-1 is an HDL-associated enzyme that protects against cardiovascular disease and is reduced in diabetes. The present study examined if serum myeloperoxidase was (i) increased in type 2 diabetes, (ii) correlated with paraoxonase-1 activity. METHODS AND RESULTS: The study was based on cross-sectional analyses of serum myeloperoxidase and paraoxonase-1 in type 2 diabetic patients and non-diabetic participants, with and without cardiovascular disease. Serum myeloperoxidase concentrations were not increased in type 2 diabetic patients without cardiovascular disease compared to non-diabetic controls. They were significantly higher in type 2 patients and non-diabetic patients with angiographically confirmed coronary disease. HDL-associated myeloperoxidase was correlated with serum myeloperoxidase (r=0.80, p<0.001) but not HDL-cholesterol (r=0.08) or apolipoprotein AI (r=0.08). Multivariate analyses showed serum myeloperoxidase to be an independent determinant of paraoxonase activities (arylesterase, p=0.024; paraoxonase, p=0.026). CONCLUSIONS: Myeloperoxidase is an independent, negative determinant of paraoxonase-1 activity, which may be one mechanism by which it promotes HDL dysfunction and increases cardiovascular risk. Increased serum myeloperoxidase is not a feature of type 2 diabetes in the absence of overt cardiovascular disease. The level of HDL-associated myeloperoxidase is determined by the serum concentration of the enzyme suggesting that, in the context of reduced HDL concentrations in diabetic patients, myeloperoxidase may have a greater impact on HDL function.|
|Keywords||Adult — Aged — Apolipoprotein A-I/blood — Aryldialkylphosphatase/*blood — Coronary Artery Disease/blood/epidemiology — Cross-Sectional Studies — Diabetes Mellitus, Type 2/*blood/*epidemiology — Enzyme Activation/physiology — Female — Humans — Lipoproteins, HDL/blood — Male — Middle Aged — Multivariate Analysis — Oxidative Stress/*physiology — Peroxidase/*blood — Predictive Value of Tests — Risk Factors|
|Research group||Lipoprotéines sériques (598)|
|JORNAYVAZ, F. R., BRULHART-MEYNET, Marie-claude, JAMES, Richard William. Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients. In: Nutrition Metabolism and Cardiovascular Diseases, 2009, vol. 19, n° 9, p. 613-619. https://archive-ouverte.unige.ch/unige:19880|